Navigation Links
Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
Date:12/10/2007

damage, was administered on a weekly or twice weekly schedule to patients with relapsed or refractory acute leukemias. Twelve of thirty patients (40 percent) who received doses of SNS-595 of 50 mg/m2 or greater on a weekly dose schedule achieved bone marrow blast reductions to less than five percent, and four of these twelve patients achieved either complete remission (CR), complete remission without platelet recovery (CRp) or complete remission with incomplete recovery of normal hematopoietic blood elements (CRi). In the twice-weekly dosing cohort, anti-leukemic activity was observed among two out of fourteen patients (14 percent) who received doses of 40 mg/m2 or greater, including one complete remission. In both arms of the study, SNS-595's anticancer activity correlated with sustained exposure to drug above a threshold plasma concentration for at least 20 hours per week of active treatment. At the maximum-tolerated-dose, this threshold was exceeded on average in both dosing schedules.

"SNS-595 is a novel chemotherapeutic agent with a distinct mechanism of action that is demonstrating both good tolerability and early signals of promising clinical activity in a group of patients with very advanced acute leukemias," said Dr. Lancet, a principal investigator for the Phase 1 trial. "I look forward to its continued clinical development in AML, both as a single agent and in combination with other cytotoxics."

The Phase 1 clinical trial was designed to evaluate the safety and tolerability of escalating doses of SNS-595 and to establish the maximum-tolerated dose in both treatment schedules. A preliminary assessment of SNS-595's anti-tumor activity as a single agent was a secondary objective of the trial. Overall, SNS-595 was generally well tolerated, with a dose-limiting toxicity of reversible Grade 3 - 4 oral mucositis. A maximum-tolerated dose of 72 mg/m2 once-weekly and 40 mg/m2 twice-weekly was established. SNS-595 exhibited consistent and predictable
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2015)... Emergency Medical Care (EMC), a New ... recently commemorated its three-year anniversary of being the only ... to 24-hour urgent care, Emergency Medical Care offers its ... time, Emergency Medical Care’s Urgent Care NYC ... eye injuries, ear infections, fevers, insect bites, burns, animal ...
(Date:3/28/2015)... 2015 One in three young athletes ... presented today at the American Orthopaedic Society for Sports ... the long term success of surgery for patients aged ... data from 242 patients who underwent ACL reconstruction between ... MBBS, FRACS, from North Sydney Orthopaedic and Sports Medicine ...
(Date:3/28/2015)... March 28, 2015 Andrew Hawley of Vintage ... Who psychedelic concert posters. The Who and the Doors played ... August 2, 1968. According to Hawley, “The Who toured the ... halls and college campuses. Perhaps the most famous Who poster ... Morrison and the Doors on August 2, 1968 at the ...
(Date:3/28/2015)... 28, 2015 Designers and Professionals of ... entitled Scratches 5K from Pixel Film Studios. , “Scratches ... any media inside Final Cut Pro X” Said Christina ... time and is an effective tool for any FCPX ... Scratches 5K's intuitive grunge overlays. Simply drag title layers ...
(Date:3/27/2015)... Miami, FL (PRWEB) March 27, 2015 ... relationship guide from dating experts Samantha Sanderson and Jason ... a frenzied buzz of media attention. The commotion surrounding ... Sean Roman, prompting him to publish an in-depth review ... emotionally devastated when the men in their lives suddenly ...
Breaking Medicine News(10 mins):Health News:Emergency Medical Care Celebrates Three Years of 24/7 Walk-In Urgent Care Services 2Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Pixel Film Studios Unveiled Scratches 5k for Final Cut Pro X Editors 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2
... St. David,s is Second Hospital Nationwide to Acquire Groundbreaking ... Medical Center today,announced its acquisition of a new robotic ... rhythm disorders that can result in a,stroke. Called the ... technology is only the second to be installed in,the ...
... Tips for Maintaining a Healthy Liver, NEW YORK, ... liver, the American Liver Foundation (ALF) today observed Liver,Awareness ... which affects,30 million Americans. Liver disease, a serious ... 7th leading cause of death among adults between the ...
... HealthSouth,Corporation (NYSE: HLS ) today announced the ... directors, effective Oct. 2, 2007. Mr. Chidsey currently,serves ... Burger King Holdings,Inc. "John brings a strong ... financial operations, capital markets, and corporate,management in a ...
... Budapest, 4 October 2007 -- Last month a collaboration ... against the deadly bird flu virus, harnessing the combined ... to boost the pace of anti-viral drug discovery. , ... ordinary PCs to form a super-sized supercomputer that is ...
... Researchers in the United States and Sweden have identified ... arthritis (RA), a chronic and debilitating inflammatory disease of ... The U.S. arm of the study involved a long-time ... Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other ...
... Business Services,announced today that they have launched ... and benefits verification. Emdeon is offering these,transactions ... Emdeon suite of,products for dental practices including ... portal. Emdeon Business Services now offers,dental practices ...
Cached Medicine News:Health News:St. David's Medical Center Implements New Robotic Technology to Treat Common Heart Rhythm Disorders 2Health News:St. David's Medical Center Implements New Robotic Technology to Treat Common Heart Rhythm Disorders 3Health News:October is Liver Awareness Month: The American Liver Foundation Urges All Americans to Pay Attention to Their Liver Every Day of the Year 2Health News:October is Liver Awareness Month: The American Liver Foundation Urges All Americans to Pay Attention to Their Liver Every Day of the Year 3Health News:HealthSouth Corporation Appoints New Member to Board of Directors 2Health News:HealthSouth Corporation Appoints New Member to Board of Directors 3Health News:Grid computing offers new hope in race against bird flu 2Health News:Researchers identify genes that increase rheumatoid arthritis risk 2Health News:Researchers identify genes that increase rheumatoid arthritis risk 3Health News:Emdeon Business Services Extends Market Leadership With New Dental Eligibility Payers 2
(Date:3/27/2015)... 27, 2015 Across the global healthcare landscape, ... in clinical development, market education, and regulatory compliance. As ... Affairs function is expected to increase in prominence and ... According to research by benchmarking firm, Best Practices, ... dedicated to Medical Affairs. Among companies in ...
(Date:3/27/2015)... 2015 /CNW/ - Covalon Technologies Ltd. (the "Company" or ... announced the issuance of an aggregate of 30,000 stock ... an aggregate of 120,500 stock options to employees and ... over three years and will be exercisable for a ... $1.40 per stock option. About Covalon ...
(Date:3/27/2015)... Object recognition technology has a unique and ... The VelaSense ® mobile platform incorporates ... productive and fulfilling lives. VelaSense ® will now ... identify objects from a one million object database, that ... databases for personal use. Visus Technology ...
Breaking Medicine Technology:Medical Affairs Capabilities Expanding in Emerging Marketplaces 2Covalon Announces Issuance of Stock Options 2VelaSense Object Recognition Technology for the Blind was unveiled at Baruch College's CCVIP 8th Annual Conference 2
Thompson surgical radiotranslucent anterior lumbar retractor system....
... Elmed Retract - ... instrument, with extra long ... improved cephalad and anterior ... (Retractor system) was designed ...
... System, a uniquely designed system combining ... two systems into one. Detachable blade ... site during retractor placement, providing better ... retractor body slides easily onto the ...
... device. Rhakoss implants represent the first ... fiber cages and allograft cadaver bone ... of first generation IBFDs while eliminating ... available materials, such as inconsistent structural ...
Medicine Products: